At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
"Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"
In Brief
A Phase 4 clinical trial evaluating Artemether-Lumefantrine Tab 20-120mg, Primaquine Phosphate 0.25 mg/kg, and 1 other intervention for Malaria,Falciparum. Completed, enrolled 280 participants across 2 sites.
Detailed Summary
This clinical trial evaluates the advantage of prolonging the therapeutic life span of Artemether-lumefantrine from 3 days to 6 days, and addition of single low dose of Primaquine 0.25mg/kg. The study will have two arms, one that will receive standard treatment of uncomplicated malaria with Artemether-lumefantrine, and the other arm will receive the prolonged dose of 6 days together with single low dose primaquine. This approach is expected to provide strategies for malaria control in an era of imminent Plasmodium falciparum resistance.
Study Details
Timeline
Interventions
Artemether-Lumefantrine Tablet 20-120mg
Primaquine Phosphate 0.25 mg/kg
Aqueous solution prepared to mimic the taste of the intervention drug.